Infliximab for the treatment of ulcerative colitis

Expert Review of Gastroenterology and Hepatology

Volumn 3, Issue 3, 2009, Pages 219-229

  Eshuis, Emma J ^a   Bemelman, Willem A ^a   Stokkers, Pieter C F ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Biologic therapy; Clinical remission; Controlled trial; Infliximab; Randomized; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; STEROID; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTEREMIA; BREAST FEEDING; CLINICAL PROTOCOL; CLINICAL TRIAL; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ESOPHAGITIS; HISTORY OF MEDICINE; HUMAN; IMMUNOGENICITY; PANCREATITIS; PATHOGENESIS; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; PREGNANCY; PRURITUS; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RHEUMATOID ARTHRITIS; SEPSIS; SINGLE DRUG DOSE; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; HUMANS; QUALITY OF LIFE; STEROIDS; TREATMENT OUTCOME;

EID: 68149145464     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.09.19     Document Type: Article

References (75)

1. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369, 1641-1657 (2007).
2. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126, 1504-1517 (2004).
3. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am. J. Gastroenterol. 99, 1371-1385 (2004).
4. Travis SP, Stange EF, Lémann M et al. European evidence-based consensus on the management of ulcerative colitis: current management. Gut (55 Suppl. 1), I16-I35 (2006).
5. Reinisch W, Sandborn WJ, Bala M et al. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm. Bowel Dis. 13, 1135-1140 (2007).
6. Hanauer SB. Review article: evolving concepts in treatment and disease modification in ulcerative colitis. Aliment. Pharmacol. Ther. 27(Suppl. 1), 15-21 (2008).
7. Gionchetti P, Rizzello F, Venturi A et al. Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis. Aliment. Pharmacol. Ther. 11, 1053-1057 (1997).
8. Mulder CJ, Fockens P, Meijer JW, van der Heide H, Wiltink EH, Tytgat GN. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur. J. Gastroenterol. Hepatol. 8, 549-553 (1996).
9. Regueiro M, Loftus EV Jr, Steinhart AH, Cohen RD. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm. Bowel Dis. 12, 979-994 (2006).
10. Campieri M, Adamo S, Valpiani D et al. Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment. Pharmacol. Ther. 17, 1471-1480 (2003).
11. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1, 1067-1070 (1974).
12. Van Assche G, D'Haens G, Noman M et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 125, 1025-1031 (2003).
13. Baumgart DC, Macdonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst. Rev. 3, CD007216 (2008).
14. Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med. 330, 1841-1845 (1994).
15. Langholz E, Munkholm P, Davidsen M, Binder V. Coarse of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 107, 3-11 (1994).
16. Henriksen M, Jahnsen J, Lygren I et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm. Bowel Dis. 12, 543-550 (2006).
17. Hueting WE, Buskens E, van der Tweel I, Gooszen HG, van Laarhoven CJ. Results and complications after ileal pouch anal anastomosis: a meta-analysis of 43 observational studies comprising 9,317 patients. Dig. Surg. 22, 69-79 (2005).
18. Remicade® (infliximab), summary of product characteristics. Centocor Inc., PA, USA (2008).
19. Remicade® (infliximab), prescribing information. Centocor Inc., PA, USA (2008).
20. Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 28, 674-688 (2008).
21. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl Acad. Sci. USA 72, 3666-3670 (1975).
22. Debets JM, Kampmeijer R, van der Linden MP, Buurman WA, van der Linden CJ. Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit. Care Med. 17, 489-494 (1989).
23. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor α in stool as a marker of intestinal inflammation. Lancet 339, 89-91 (1992).
24. Brennan FM, Maini RN, Feldmann M. TNF α - a pivotal role in rheumatoid arthritis? Br. J. Rheumatol. 31, 293-298 (1992).
25. Knight DM, Trinh H, Le J et al. Construction and initial characterization of a mouse - human chimeric anti-TNF antibody. Mol. Immunol 30, 1443-1453 (1993).
26. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat. Rev. Immunol. 2, 364-371 (2002).
27. Feldmann M, Elliott MJ, Woody JN, Maini RN. Anti-tumor necrosis factor-α therapy of rheumatoid arthritis. Adv. Immunol. 64, 283-350 (1997).
28. van Dullemen HM, van Deventer SJ, Hommes DW et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109, 129-135 (1995).
29. Hommes DW, van de Heisteeg BH, van der Spek M, Bartelsman JF, van Deventer SJ. Infliximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital. Inflamm. Bowel Dis. 8, 81-86 (2002).
30. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor-α blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. 3, CD005112 (2006).
31. Himmel ME, Hardenberg G, Piccirillo CA, Steiner TS, Levings MK. The role of T-regulatory cells and Toll-like receptors in the pathogenesis of human inflammatory bowel disease. Immunology 125, 145-153 (2008).
32. Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin. Pharmacokinet. 46, 645-660 (2007).
33. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117, 244-279 (2008).
34. Siddiqui MA, Scott LJ. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. Drugs 65, 2179-2208 (2005).
35. Boyle A, Tawadros R, Zhu Y. Comparative pharmacokinetics of single and multiple-dose infliximab in Crohn's disease patients. Gastroenterology 122, A614-A615 (2002).
36. Järnerot G, Hertervig E, Friis-Liby I et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128, 1805-1811 (2005).
37. Probert CS, Hearing SD, Schreiber S et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 52, 998-1002 (2003).
38. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353, 2462-2476 (2005).
39. Sands BE, Tremaine WJ, Sandborn WJ et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm. Bowel Dis. 7, 83-88 (2001).
40. Armuzzi A, De PB, Lupascu A et al. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur. Rev. Med. Pharmacol. Sci. 8, 231-233 (2004).
41. Ochsenkuhn T, Sackmann M, Goke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur. J. Gastroenterol. Hepatol. 16, 1167-1171 (2004).
42. Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: infliximab therapy in ulcerative colitis. Aliment. Pharmacol. Ther. 25, 19-37 (2007).
43. Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am. J. Gastroenterol. 87, 971-976 (1992).
44. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 317, 1625-1629 (1987).
45. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br. Med. J. 1, 89-92 (1964).
46. Nordin K, Pahlman L, Larsson K, Sundberg-Hjelm M, Loof L. Health-related quality of life and psychological distress in a population-based sample of Swedish patients with inflammatory bowel disease. Scand. J. Gastroenterol. 37, 450-457 (2002).
47. Irvine EJ. Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm. Bowel Dis. 14, 554-565 (2008).
48. Feagan BG, Reinisch W, Rutgeerts P et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am. J. Gastroenterol. 102, 794-802 (2007).
49. Hanauer SB. Infliximab or cyclosporine for severe ulcerative colitis. Gastroenterology 129, 1358-1359 (2005).
50. Maser EA, Deconda D, Lichtiger S, Ullman T, Present DH, Kornbluth A. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin. Gastroenterol. Hepatol. 6, 1112-1116 (2008).
51. Periodical Safety Update Report (PSUR) 2008. Centocor Inc., PA, USA (2008).
52. Caviglia R, Boskoski I, Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: safety and, tolerability issues. Expert Opin. Drug Saf. 7, 617-632 (2008).
53. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am. J. Gastroenterol. 99, 2385-2392 (2004).
54. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin. Gastroenterol. Hepatol. 4, 621-630 (2006).
55. Colombel JF, Prantera C, Rutgeerts P et al. No new safety signals identified in Crohn's disease patients treated with infliximab in an interim review of the ENCORE registry. Gastroenterology, 134, A472 (2008).
56. Ulcerative Colitis European Registry. A Prospective, Observational, Non-interventional, Post-marketing Safety Surveillance Program. Schering-Plough Research Institute, NJ, USA (2008).
57. Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 57, 1639-1641 (2008).
58. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 56, 1226-1231 (2007).
59. Rutgeerts P, Feagan BG, Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126, 402-413 (2004).
60. Deshpande AR, Abreu MT. Combination therapy with infliximab and immunomodulators: is the glass half empty? Gastroenterology 134, 2161-2163 (2008).
61. Van Assche G, Magdelaine-Beuzelin C, D'Haens G et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134, 1861-1868 (2008).
62. Hanauer SB. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut 56, 1181-1183 (2007).
63. Toruner M, Loftus EV Jr, Harmsen WS et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134, 929-936 (2008).
64. Kohn A, Daperno M, Armuzzi A et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment. Pharmacol. Ther. 26, 747-756 (2007).
65. Lees CW, Heys D, Ho GT et al. A retrospective analysis of the efficacy a nd safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment. Pharmacol. Ther. 26, 411-419 (2007).
66. Mor IJ, Vogel JD, da Luz MA, Shen B, Hammel J, Remzi FH. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis. Colon Rectum 51, 1202-1207 (2008).
67. Selvasekar CR, Cima RR, Larson DW et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J. Am. Coll. Surg. 204, 956-962 (2007).
68. Ferrante M, D'Hoore A, Vermeire S et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm. Bowel Dis. DOI:10.1002/ ibd.20863 (2009).
69. O'Donnell S, O'Morain C. Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception. Aliment. Pharmacol. Ther. 27, 885-894 (2008).
70. Stengel JZ, Arnold HL. Is infliximab safe to use while breastfeeding? World J. Gastroenterol. 14, 3085-3087 (2008).
71. Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M. Infliximab efficacy in pediatric ulcerative colitis. Inflamm. Bowel Dis. 11, 213-238 (2005).
72. Mamula P, Markowitz JE, Cohen LJ, von Allmen D, Baldassano RN. Infliximab in pediatric ulcerative colitis: two-year follow-up. J. Pediatr. Gastroenterol. Nutr. 38, 298-301 (2004).
73. Russell GH, Katz AJ. Infliximab is effective in acute but not chronic childhood ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 39, 166-170 (2004).
74. McGinnis JK, Murray KF. Infliximab for ulcerative colitis in children and adolescents. J. Clin. Gastroenterol. 42, 875-879 (2008).
75. Franke A, Balschun T, Karlsen TH et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat. Genet. 40, 1319-1323 (2008).